Literature DB >> 16688182

IL-23 promotes tumour incidence and growth.

John L Langowski1, Xueqing Zhang, Lingling Wu, Jeanine D Mattson, Taiying Chen, Kathy Smith, Beth Basham, Terrill McClanahan, Robert A Kastelein, Martin Oft.   

Abstract

Chronic inflammation has long been associated with increased incidence of malignancy and similarities in the regulatory mechanisms have been suggested for more than a century. Infiltration of innate immune cells, elevated activities of matrix metalloproteases and increased angiogenesis and vasculature density are a few examples of the similarities between chronic and tumour-associated inflammation. Conversely, the elimination of early malignant lesions by immune surveillance, which relies on the cytotoxic activity of tumour-infiltrating T cells or intra-epithelial lymphocytes, is thought to be rate-limiting for the risk to develop cancer. Here we show a molecular connection between the rise in tumour-associated inflammation and a lack of tumour immune surveillance. Expression of the heterodimeric cytokine interleukin (IL)-23, but not of its close relative IL-12, is increased in human tumours. Expression of these cytokines antagonistically regulates local inflammatory responses in the tumour microenvironment and infiltration of intra-epithelial lymphocytes. Whereas IL-12 promotes infiltration of cytotoxic T cells, IL-23 promotes inflammatory responses such as upregulation of the matrix metalloprotease MMP9, and increases angiogenesis but reduces CD8 T-cell infiltration. Genetic deletion or antibody-mediated elimination of IL-23 leads to increased infiltration of cytotoxic T cells into the transformed tissue, rendering a protective effect against chemically induced carcinogenesis. Finally, transplanted tumours are growth-restricted in hosts depleted for IL-23 or in IL-23-receptor-deficient mice. Although many strategies for immune therapy of cancer attempt to stimulate an immune response against solid tumours, infiltration of effector cells into the tumour tissue often appears to be a critical hurdle. We show that IL-23 is an important molecular link between tumour-promoting pro-inflammatory processes and the failure of the adaptive immune surveillance to infiltrate tumours.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16688182     DOI: 10.1038/nature04808

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  368 in total

1.  A novel immunoregulatory function for IL-23: Inhibition of IL-12-dependent IFN-γ production.

Authors:  Amy N Sieve; Karen D Meeks; Suheung Lee; Rance E Berg
Journal:  Eur J Immunol       Date:  2010-08       Impact factor: 5.532

2.  The expression of interleukin (IL)-17 and IL-17 receptor and MMP-9 in human pituitary adenomas.

Authors:  Lubin Qiu; Dongsheng He; Xiang Fan; Zhi Li; Chuangxin Liao; Yonghong Zhu; Haijun Wang
Journal:  Pituitary       Date:  2011-09       Impact factor: 4.107

3.  Posttranscriptional regulation of IL-23 expression by IFN-gamma through tristetraprolin.

Authors:  Xuesong Qian; Huan Ning; Jidong Zhang; Daniel F Hoft; Deborah J Stumpo; Perry J Blackshear; Jianguo Liu
Journal:  J Immunol       Date:  2011-04-22       Impact factor: 5.422

4.  TGF-β receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms.

Authors:  Sergey V Novitskiy; Michael W Pickup; Agnieszka E Gorska; Philip Owens; Anna Chytil; Mary Aakre; Huiyun Wu; Yu Shyr; Harold L Moses
Journal:  Cancer Discov       Date:  2011-10       Impact factor: 39.397

Review 5.  Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets.

Authors:  Pauline L Martin; Peter J Bugelski
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 6.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

7.  Immune chaperone gp96 drives the contributions of macrophages to inflammatory colon tumorigenesis.

Authors:  Crystal Morales; Saleh Rachidi; Feng Hong; Shaoli Sun; Xinshou Ouyang; Caroline Wallace; Yongliang Zhang; Elizabeth Garret-Mayer; Jennifer Wu; Bei Liu; Zihai Li
Journal:  Cancer Res       Date:  2013-12-09       Impact factor: 12.701

8.  Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth.

Authors:  Sergei I Grivennikov; Kepeng Wang; Daniel Mucida; C Andrew Stewart; Bernd Schnabl; Dominik Jauch; Koji Taniguchi; Guann-Yi Yu; Christoph H Osterreicher; Kenneth E Hung; Christian Datz; Ying Feng; Eric R Fearon; Mohamed Oukka; Lino Tessarollo; Vincenzo Coppola; Felix Yarovinsky; Hilde Cheroutre; Lars Eckmann; Giorgio Trinchieri; Michael Karin
Journal:  Nature       Date:  2012-11-08       Impact factor: 49.962

9.  Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells.

Authors:  I H Chan; R Jain; M S Tessmer; D Gorman; R Mangadu; M Sathe; F Vives; C Moon; E Penaflor; S Turner; G Ayanoglu; C Chang; B Basham; J B Mumm; R H Pierce; J H Yearley; T K McClanahan; J H Phillips; D J Cua; E P Bowman; R A Kastelein; D LaFace
Journal:  Mucosal Immunol       Date:  2013-11-27       Impact factor: 7.313

Review 10.  Regulation and function of proinflammatory TH17 cells.

Authors:  Gustavo J Martinez; Roza I Nurieva; Xuexian O Yang; Chen Dong
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.